Bone MicroArchitecture in Acromegaly

NCT03225040

Last updated date
Study Location
Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, 10032, United States
Contact
212-305-4921

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

212-305-4921

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acromegaly, Osteoporosis Risk
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Individuals with acromegaly

- On pegvisomant therapy with a normal IGF-1 level for at least 1 year

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Malignancy (except cured basal, squamous cell skin carcinoma or other cured cancers
free from recurrence > 3 years)


- Pregnancy or lactation within last 12 months


- Untreated primary hyperparathyroidism, hyper- or hypothyroidism


- Cushing's syndrome


- Prolactin-secreting pituitary adenoma


- GH deficiency


- On current drug therapy for osteoporosis


- Diabetes mellitus


- Renal insufficiency


- Liver disease


- Current or past use of glucocorticoids (more than physiologic dose), anticonvulsants,
anticoagulants, methotrexate, aromatase inhibitors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acromegaly, Osteoporosis RiskBone MicroArchitecture in Acromegaly
NCT03225040
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Bone MicroArchitecture in Acromegaly
Official Title Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly
Brief Summary The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to describe the bone architecture and associated biochemical indices of bone turnover and metabolism in patients with active acromegaly and how these are altered with treatment of the disease.
Detailed Description Growth hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) are important regulators of bone modeling and remodeling, fundamental to maintenance of normal skeletal integrity. In acromegaly, a disease characterized by longstanding exposure to excess GH and IGF-1, these hormones induce marked skeletal changes. Most dual energy X-ray absorptiometry (DXA) studies report that bone mineral density (BMD) is normal in acromegaly. Despite this, however, there is mounting evidence that bone health is adversely affected in patients with both active and successfully treated acromegaly.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Peripheral blood specimens
Sampling Method Non-Probability Sample
Study Population

25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year will be studied.

Patients will be on stable doses of any pituitary hormone supplements for 3 months prior to study entry including gonadal steroid replacement for men or premenopausal women. Hypogonadal men and premenopausal women will be replaced with clinically appropriate sex steroid replacement. Subjects will be 50% females.

Condition
  • Acromegaly
  • Osteoporosis Risk
Intervention Drug: Pegvisomant
Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
Other Name: Somavert
Study Groups/Cohorts Acromegaly patients on pegvisomant
25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
Intervention: Drug: Pegvisomant
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: July 19, 2017)
25
Original Estimated Enrollment Same as current
Estimated Study Completion Date March 2020
Estimated Primary Completion Date March 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Individuals with acromegaly
  • On pegvisomant therapy with a normal IGF-1 level for at least 1 year

Exclusion Criteria:

  • Malignancy (except cured basal, squamous cell skin carcinoma or other cured cancers free from recurrence > 3 years)
  • Pregnancy or lactation within last 12 months
  • Untreated primary hyperparathyroidism, hyper- or hypothyroidism
  • Cushing's syndrome
  • Prolactin-secreting pituitary adenoma
  • GH deficiency
  • On current drug therapy for osteoporosis
  • Diabetes mellitus
  • Renal insufficiency
  • Liver disease
  • Current or past use of glucocorticoids (more than physiologic dose), anticonvulsants, anticoagulants, methotrexate, aromatase inhibitors
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Carlos Reyes-Vidal, MD212-305-4921[email protected]
Contact: Pamela Freda, MD212-305-2254
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03225040
Other Study ID Numbers AAAE5304
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement
Plan to Share IPD:Undecided
Responsible Party Pamela U. Freda, Columbia University
Study Sponsor Columbia University
Collaborators Pfizer
Investigators
Principal Investigator:Pamela Freda, MDColumbia University
PRS Account Columbia University
Verification Date February 2019